SURMOUNT-OSA included two randomized trials of tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnea. Both measured change in the apnea–hypopnea index, or AHI, after 52 weeks. The index counts breathing interruptions or reductions per hour of sleep under specified scoring rules.
Why were there two studies?
One trial enrolled adults who were not using positive airway pressure therapy, or PAP, at baseline. The other enrolled adults who were using PAP. Each trial randomly assigned participants to tirzepatide or placebo. Compare each assigned group with the placebo group from the same trial.
What did the 52-week results show?
In the trial without PAP at baseline, the estimated reduction versus placebo was 20.0 events per hour. In the trial with PAP at baseline, the estimated reduction versus placebo was 23.8 events per hour. These are between-group differences in an event rate, so they should not be described as percentages of weight lost or as the share of people whose apnea resolved.
How should you read the rest of the paper?
Check the baseline AHI, confidence intervals and adverse-event reporting. The investigators also measured changes beyond AHI, including other sleep-related outcomes. When you cite a result, name the study group and the unit. Doing so makes it possible for readers to check the number against the original table.
What did the FDA approve?
In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity. The current prescribing information describes the specific indication and warnings. That product label is separate from the evidence record for other molecules under study.
Sources and further reading
SURMOUNT-OSA primary trial report · FDA announcement on the Zepbound OSA indication · Current U.S. Zepbound prescribing information